表紙
市場調查報告書

嗜中性白血球彈性酵素:開發中產品分析

Neutrophil Elastase - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 365751
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
嗜中性白血球彈性酵素:開發中產品分析 Neutrophil Elastase - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 65 Pages
簡介

本報告提供以嗜中性白血球彈性酵素為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

嗜中性白血球彈性酵素 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Cantex Pharmaceuticals, Inc.
  • Chiesi Farmaceutici SpA
  • Kamada Ltd.
  • Polyphor Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1989TDB

Summary

According to the recently published report 'Neutrophil Elastase - Pipeline Review, H2 2019'; Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Neutrophil elastase is a serine proteinase. It is secreted from neutrophils. It is involved in inflammatory diseases, including idiopathic pulmonary fibrosis, rheumatoid arthritis, adult respiratory distress syndrome, and cystic fibrosis. It modifies the functions of natural killer cells, monocytes and granulocytes. It inhibits C5a-dependent neutrophil enzyme release and chemotaxis.

The report 'Neutrophil Elastase - Pipeline Review, H2 2019' outlays comprehensive information on the Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Discovery stages are 6, 1 and 1 respectively.

Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Respiratory, Immunology, Genetic Disorders, Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Infectious Disease and Metabolic Disorders which include indications Cystic Fibrosis, Inflammation, Alpha-1 Antitrypsin Deficiency (A1AD), Bronchiectasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bronchiolitis Obliterans, Chronic Obstructive Pulmonary Disease (COPD), Graft Versus Host Disease (GVHD), Ischemia Reperfusion Injury, Lung Disease, Lung Injury, Lung Transplant Rejection, Myelodysplastic Syndrome, Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), Non-Alcoholic Steatohepatitis (NASH), Primary Ciliary Dyskinesia, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Traumatic Brain Injury, Type 2 Diabetes and Vascular Injury.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)
  • The report reviews Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Overview
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Chiesi Farmaceutici SpA
  • Chimerix Inc
  • Kyorin Pharmaceutical Co Ltd
  • LifeMax Laboratories Inc
  • pH Pharma Co Ltd
  • Proteo Inc
  • Santhera Pharmaceuticals Holding AG
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Drug Profiles
  • alvelestat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CHF-6333 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dociparstat sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KRP-109 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LM-030 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PHP-303 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • POL-6014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sivelestat sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule 1 to Inhibit ELANE for Immunology, Oncology and Respiratory Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ELANE for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Neutrophil Elastase for Lung Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tiprelestat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Dormant Products
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Discontinued Products
  • Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting
  • Nov 13, 2019: LifeMax receives Orphan Drug Designation from the European Commission for LM-030 for the treatment of Netherton Syndrome
  • Sep 10, 2019: Santhera announces publication of phase I clinical data with POL6014 in Journal of Cystic Fibrosis
  • Jul 18, 2019: LifeMax receives rare pediatric disease designation for LM-030 for the treatment of netherton syndrome
  • Jun 27, 2019: LifeMax receives orphan drug designation from the United States Food & Drug Administration for LM-030 for the treatment of Netherton Syndrome
  • Nov 05, 2018: First patient dosed in phase 2 alpha-1 antitrypsin deficiency study
  • Oct 24, 2018: Santhera announces start of phase Ib/IIa trial with POL6014 in patients with cystic fibrosis
  • Oct 15, 2018: Santhera receives positive opinion for Orphan Drug Designation in the EU for POL6014 in Cystic Fibrosis
  • Sep 13, 2018: LifeMax appoints Laman Alani, Ph.D., as VP of Product Development
  • Jun 04, 2018: Cantex Pharmaceuticals Announces That Clinical Trial Data For CX-01 In Refractory Acute Myeloid Leukemia And Myelodysplastic Syndrome Will Be Presented At The 2018 ASCO Annual Meeting
  • Mar 12, 2018: Publication in Blood Advances Reports that the Combination of Cantex Pharmaceuticals CX-01 with Chemotherapy for the Treatment of Acute Myeloid Leukemia Showed Encouraging Complete Remission Rates and Rapid Platelet Count Recovery
  • Jan 03, 2018: Cantex Pharmaceuticals Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
  • Jun 06, 2016: Polyphor successfully completes clinical Phase I study with POL6014 targeting life threatening lung diseases including cystic fibrosis
  • Jun 06, 2016: Proteo receives US$ 1 million grant for a new Elafin drug formulation
  • Mar 23, 2016: Polyphor announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to advance the clinical development of POL6014
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by Chiesi Farmaceutici SpA, H2 2019
  • Pipeline by Chimerix Inc, H2 2019
  • Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
  • Pipeline by LifeMax Laboratories Inc, H2 2019
  • Pipeline by pH Pharma Co Ltd, H2 2019
  • Pipeline by Proteo Inc, H2 2019
  • Pipeline by Santhera Pharmaceuticals Holding AG, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019